Dipeptide Diaminobutyroyl Benzylamide Diacetate
/ Synthetic snake-venom mimetic dipeptide; Waglerin-1-derived; nicotinic acetylcholine receptor antagonist; INCI 'Dipeptide Diaminobutyroyl Benzylamide Diacetate'ALIAS · Syn-Ake variant · Waglerin mimetic · Dipeptide Diaminobutyroyl Benzylamide Diacetate (INCI)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. The extended INCI-named diacetate salt form of the Syn-Ake / Tripeptide-3 chemistry — a synthetic snake-venom mimetic dipeptide derived structurally from waglerin-1, a peptide isolated from Tropidolaemus wagleri venom. Marketed by cosmetic-ingredient suppliers as a topical 'Botox-alternative' active. Independent published characterisation specific to this INCI form is sparse; mechanistic claims are inherited from the parent waglerin nicotinic acetylcholine receptor (nAChR) literature.
Waglerin-1, the natural template, is a 22-residue peptide from Tropidolaemus wagleri venom that acts as a competitive antagonist at the muscle-type nicotinic acetylcholine receptor, selective for the alpha-1 / epsilon subunit interface. The cosmetic mimetic is a much-shortened diaminobutyroyl-benzylamide dipeptide claimed in supplier literature to retain partial nAChR-antagonist activity at the neuromuscular junction of facial mimetic muscle, attenuating acetylcholine-driven contraction. Whether topical application produces meaningful epidermal or dermal penetration to the underlying neuromuscular junction has not been demonstrated in independent pharmacokinetic work.
Tier 4. The mechanistic chain (waglerin nAChR antagonism is real; the dipeptide retains some receptor-binding activity in vitro) is plausible. Topical-efficacy claims in cosmetic application rest predominantly on industry-authored or supplier-sponsored studies that have not been independently replicated in the indexed primary literature.
No formal safety database for the topical cosmetic active beyond standard supplier patch-test data. Systemic exposure from topical application is presumed low but has not been quantified. Theoretical concern: competitive nAChR antagonism is the mechanism of clinical neuromuscular blockers; the cosmetic mimetic's potency is asserted to be far below therapeutic thresholds, but independent confirmation is limited.
Regulatory status
- FDA status:
- Not FDA-approved
Cosmetic INCI nomenclature creates frequent confusion with the simpler 'Tripeptide-3' / Syn-Ake form — both compounds are sold under the 'Syn-Ake' trade umbrella by Pentapharm (now part of DSM). The diaminobutyroyl-benzylamide diacetate form is the extended salt; the tripeptide-3 form is the parent. Vendor product specifications often do not disclose which form is supplied. Topical efficacy versus placebo at the doses used in cosmetic products has not been established in independent randomised work.